Lonza Articles
Lonza to invest in new antibody drug conjugate manufacturing capacity to meet growing demand
8 January 2013
Lonza and Agennix link up for talactoferrin production
12 April 2012
Mesoblast and Lonza establish strategic global manufacturing alliance for stem cell products
28 September 2011
Lonza invests $27.5 million to expand cytotoxic manufacturing to serve growing oncology API market
13 May 2011
Lonza to invest £16 million to expand a UK facility
30 March 2011
GlaxoSmithKline sells Croatian research center to Galapagos, names new CFO and enters supply deal with Lonza; EMEA update on Avandia and Pandemrix
9 September 2010
Burst of M&A activity in pharma during 2009 led by mega-deals from Pfizer/Wyeth and Merck & Co/S-P
4 February 2010
Lonza rides to the rescue of Patheon with a $460 million bid
21 August 2009
EU Commission clears Teva/Lonza JV
15 May 2009
Teva and Lonza form biosimilars JV
26 January 2009
Crucell licenses PERMEXIS to Lonza
6 October 2008
Lonza profit up 83% on sale of stake in Polynt
4 August 2008
Novartis and Lonza sign production deal
21 July 2008
Lehman analysts rate Lonza overweight
14 July 2008
Singapore reinforces position as a global site for pharma and biotech; output quadruples
30 June 2008
Almirall owners buy stake in Lonza
28 April 2008
Call for UK govt biotech subsidy to fund Centers of Excellence
3 December 2007
Sanofi Pasteur begins Ph II flu vacc study
19 November 2007
Tercica in manufacturing deal with Lonza
21 May 2007
Lonza in two biomanufacturing deals with Genentech
13 November 2006
Lonza buys two Cambrex units for $460 million
30 October 2006
Lonza to invest $200M in Chinese operations
17 April 2006
Lonza acquires UCB-Bioprods for 120M euros
13 March 2006
Lonza and Bio*One invest in cell culture plant
20 February 2006
Lonza licenses GS System to Genentech
20 February 2006
Switzerland's Lonza expands in Visp, sets up R&D in China
19 September 2005
Lonza/Bio*One JV for Singapore plant
22 August 2005
Celltrion to make biologicals for B-MS
27 June 2005
UCB/Lonza supply deal
23 May 2005
Lonza Biologics to make Aurexis for Inhibitex
22 November 2004
TKT prevails in UK epoietin patent case
1 November 2004
Appointments at Schering-Plough Research Institute
20 September 2004
TKT in production deal for Dynepo with Lonza
9 August 2004
Codexis and Lonza commercialize novel chiral process
2 August 2004
Lonza signs niacin production deal with Innovite
2 August 2004
Stefan Borgas joins Lonza as CEO
24 May 2004
Y's Thera and Lonza collaborate
12 April 2004
Stock Commentary - New York
23 February 2004
Lonza reports FY2003; lowers 2004 guidance
26 January 2004
CAT and Lonza extend antibody deal
26 January 2004
Lonza and Vaccinex in antibody discovery alliance
21 July 2003
UK's Celltech in supply deal with Lonza
21 July 2003
Lonza issues warning as market worsens
2 June 2003
Lonza issues profit warning as markets worsen
26 May 2003
Lonza invests 100M SwFr in new plant
7 April 2003
Lonza further strengthens oligonucleotide business
3 March 2003
Lonza expands microbial fermenation capacity
3 February 2003
Lonza to manufacture antibody candidate for Alexion
13 January 2003
Lonza group shows strong growth as CEO quits
28 January 2002
CAT losses widen as chief executive decides to move on
27 November 2001
DSM Life Science products assessed by broker
1 July 1999
UK Biotech Firms Back In Vogue With Investors?
5 November 1998
CellTech Makes Solid Six-Month Progress
19 May 1998
Celltech Sells Rest Of Lonza Bio For $17.2 M
8 January 1998
Strong Financials Back Celltech's R&D
10 March 1997
Acquisitions And Mergers Continue, Led By Novartis
6 January 1997
Celltech Sells Biologics Unit
17 June 1996
Turnover And Profit Rises Planned at Lonza
29 April 1996
Showing 1-72 of 72 articles
- 1
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Is the diabetes market facing a blockbuster-free future?
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
